<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d388">
    <sentence id="DDI-DrugBank.d388.s0" text="Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with beta-blocking agents.">
        <entity id="DDI-DrugBank.d388.s0.e0" charOffset="0-28"
            type="group" text="Catecholamine-depleting drugs"/>
        <entity id="DDI-DrugBank.d388.s0.e1" charOffset="39-47"
            type="drug" text="reserpine"/>
        <entity id="DDI-DrugBank.d388.s0.e2" charOffset="94-113"
            type="group" text="beta-blocking agents"/>
        <ddi id="DDI-DrugBank.d388.s0.d0" e1="DDI-DrugBank.d388.s0.e0"
            e2="DDI-DrugBank.d388.s0.e2" type="effect"/>
        <ddi id="DDI-DrugBank.d388.s0.d1" e1="DDI-DrugBank.d388.s0.e1"
            e2="DDI-DrugBank.d388.s0.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d388.s1" text="Patients treated with acebutolol plus catecholamine depletors should, therefore, be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia.">
        <entity id="DDI-DrugBank.d388.s1.e0" charOffset="22-31"
            type="drug" text="acebutolol"/>
        <entity id="DDI-DrugBank.d388.s1.e1" charOffset="38-60"
            type="group" text="catecholamine depletors"/>
        <ddi id="DDI-DrugBank.d388.s1.d0" e1="DDI-DrugBank.d388.s1.e0"
            e2="DDI-DrugBank.d388.s1.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d388.s2" text="Exaggerated hypertensive responses have been reported from the combined use of beta-adrenergic antagonists and alpha-adrenergic stimulants, including those contained in proprietary cold remedies and vasoconstrictive nasal drops.">
        <entity id="DDI-DrugBank.d388.s2.e0" charOffset="79-105"
            type="group" text="beta-adrenergic antagonists"/>
        <entity id="DDI-DrugBank.d388.s2.e1" charOffset="111-137"
            type="group" text="alpha-adrenergic stimulants"/>
        <ddi id="DDI-DrugBank.d388.s2.d0" e1="DDI-DrugBank.d388.s2.e0"
            e2="DDI-DrugBank.d388.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d388.s3" text="Patients receiving beta-blockers should be warned of this potential hazard.">
        <entity id="DDI-DrugBank.d388.s3.e0" charOffset="19-31"
            type="group" text="beta-blockers"/>
    </sentence>
    <sentence id="DDI-DrugBank.d388.s4" text="Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by nonsteroidal anti-inflammatory drugs has been reported.">
        <entity id="DDI-DrugBank.d388.s4.e0" charOffset="43-75"
            type="group" text="beta-adrenoceptor blocking agents"/>
        <entity id="DDI-DrugBank.d388.s4.e1" charOffset="80-115"
            type="group" text="nonsteroidal anti-inflammatory drugs"/>
        <ddi id="DDI-DrugBank.d388.s4.d0" e1="DDI-DrugBank.d388.s4.e0"
            e2="DDI-DrugBank.d388.s4.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d388.s5" text="No significant interactions with digoxin, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed.">
        <entity id="DDI-DrugBank.d388.s5.e0" charOffset="33-39"
            type="drug" text="digoxin"/>
        <entity id="DDI-DrugBank.d388.s5.e1" charOffset="42-60"
            type="drug" text="hydrochlorothiazide"/>
        <entity id="DDI-DrugBank.d388.s5.e2" charOffset="63-73"
            type="drug" text="hydralazine"/>
        <entity id="DDI-DrugBank.d388.s5.e3" charOffset="76-89"
            type="drug" text="sulfinpyrazone"/>
        <entity id="DDI-DrugBank.d388.s5.e4" charOffset="97-110"
            type="group" text="contraceptives"/>
        <entity id="DDI-DrugBank.d388.s5.e5" charOffset="113-123"
            type="drug" text="tolbutamide"/>
        <entity id="DDI-DrugBank.d388.s5.e6" charOffset="129-136"
            type="drug" text="warfarin"/>
    </sentence>
</document>
